Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Strata Critical Medical (SRTA) over the last 7 years, with Q3 2025 value amounting to -$40.1 million.

  • Strata Critical Medical's Free Cash Flow fell 125928.18% to -$40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.7 million, marking a year-over-year decrease of 5027.34%. This contributed to the annual value of -$33.4 million for FY2024, which is 308.78% up from last year.
  • Per Strata Critical Medical's latest filing, its Free Cash Flow stood at -$40.1 million for Q3 2025, which was down 125928.18% from -$5.4 million recorded in Q2 2025.
  • Strata Critical Medical's 5-year Free Cash Flow high stood at $1.3 million for Q3 2023, and its period low was -$40.1 million during Q3 2025.
  • Its 5-year average for Free Cash Flow is -$10.6 million, with a median of -$9.0 million in 2022.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 375332.23% in 2021, then soared by 8249.53% in 2025.
  • Strata Critical Medical's Free Cash Flow (Quarter) stood at -$6.2 million in 2021, then tumbled by 46.07% to -$9.1 million in 2022, then dropped by 2.51% to -$9.3 million in 2023, then skyrocketed by 32.14% to -$6.3 million in 2024, then plummeted by 532.8% to -$40.1 million in 2025.
  • Its Free Cash Flow stands at -$40.1 million for Q3 2025, versus -$5.4 million for Q2 2025 and -$2.9 million for Q1 2025.